• Ziqiao Feng, Yunqiao Zhang, Xu You, Wenyu Zhang, Yuhan Ma, Qing Long, Zijun Liu, Wei Hao, Yong Zeng, and Zhaowei Teng.
• Kunming Medical University Sixth Affiliated Hospital, Yuxi, Yunnan.
• Medicine (Baltimore). 2020 Apr 1; 99 (15): e19694e19694.

BackgroundTo evaluate the association between risperidone use and interleukin-6 (IL-6) levels by conducting a meta-analysis of controlled before-and-after studies.MethodsStudies were identified through a systematic search of PubMed and Embase. The mean and standardized differences were extracted to calculate the standardized mean differences. IL-6 levels were compared in patients with schizophrenia before and after risperidone treatment.ResultsTen studies were included in the final meta-analysis. The primary findings from our study suggest that there was a significant decrease in serum IL-6 levels after risperidone treatment (P = .021). A subgroup analysis revealed the sources of heterogeneity. The sensitivity analysis indicated that the results were stable, and no publication bias was observed.ConclusionsThe present meta-analysis provides evidence that risperidone can significantly reduce IL-6 levels in schizophrenia. IL-6 is a potential biomarker of the pathophysiology and clinical processes of schizophrenia.

19 keywords...

hide…